Hightlight:The effect of orlistat on glycemic control and weight loss in overweight or obese type 2 diabetes mellitus patients was determinedHbA1c and FPG level in overweight and obese type 2 diabetes mellitus patient can improved by orlistat as an adjuvant therapy. Abstract:Risk of Type 2 diabetes mellitus (T2DM) increases steadily with increasing overweight and obesity, and these two-health problems are emerging epidemics worldwide. Orlistat, a lipase inhibitor for weight loss drug, is often used in T2DM medication as adjuvant therapy, but effectiveness of the drug for improving glycemic control on T2DM patients is unclear. This study was to determine the effect of orlistat on glycemic control and weight loss in overweight or obese patients with T2DM. Term “Orlistat” AND “(obesity OR overweight)” AND “(HbA1c OR A1C)” AND “diabetes” were systematically searched in Pubmed and Science Direct web databases up to March 2021. Only randomized controlled study (RCT) methods studies were included in this study. Collected final samples were presented in a table with narrative review. There were 9 RCT studies with a total 2,175 subjects that met inclusion criteria. Of the sample, 360 mg/day orlistat as an adjuvant therapy, was administered to overweight or obese T2DM patients together with hypocaloric intake (8 studies) or without hypocaloric intake (1 study) intervention. They were examined for 12-52 weeks. From 2 short-term (12 weeks) studies, one study revealed that orlistat improved HbA1c and fasting plasma glucose (FPG) level significantly, while one study showed no significant effect compared to placebo. Seven other studies (long term observation) had found that orlistat significantly improved HbA1c and FPG level. All studies found that orlistat significantly reduced body weight. As an adjuvant therapy, Orlistat improved HbA1c and FPG level in overweight and obese T2DM patients.

Background: U wave inversion and presence of stenosis of left anterior descending/left main coronary remains unclear. When this wave can be considered for diagnosis, influencing factors, and the patient's clinical condition, there are still no papers that discuss it Methods: A systematic search was conducted through PubMed/MEDLINE and ScienceDirect databases. This systematic review used all studies in the field of U wave inversion in correlation with the presence of stenosis of left anterior descending/left main coronary artery indefinitely. Result: The search yielded 22 studies involving a total of 2637 patients were obtained for the present study. About 11 studies reported exercise induced U waves, while 8 studies reported U wave in resting patients. The presence of U wave was frequently found in patients during angina attack, however 6 studies reported U wave in absence of angina attack patients. The incidences of U wave inversion in LAD stenosis were reported in 14 studies, 2 studies reported the presence of prominent U wave in LAD stenosis, and 4 studies reported both waves were found in patients with LAD stenosis. About 13 studies reported angina attack in patients with LAD narrowing. Conclusion: Inverted U waves are associated with the incidence of LAD/LMCA stenosis and are more common than prominent U waves in patients with symptomatic chest pain. These waves can be identified in patients either at rest or during exercise testing.

Nasopharyngeal carcinoma (NPC) is a malignant carcinoma that appears in the epithelial lining of the nasopharyngeal mucosa. Genetic predisposition, environmental risk factors, nutritional risk factors, and Epstein-Barr virus (EBV) infection are the main risk factors for NPC. Epstein-Barr virus, a human cancer-associated virus, is present in more than 90% of people worldwide. Latent Membrane Protein 1 (LMP1) has been identified as the main Epstein-Barr virus converting oncoprotein. LMP1 was shown to be present in NPC tumor tissues, suggesting a potential role for LMP1 in EBV-mediated carcinogenesis. LMP1 exerts several oncogenic properties and has the ability to transform epithelial cells through the activation of numerous signaling pathways and the control of the expression of different oncogenes and tumor-suppressor genes. the process by which tumor traits such cell proliferation, apoptosis resistance, invasion and motility, and angiogenesis are produced and maintained.